<DOC>
	<DOCNO>NCT02351037</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability ibrutinib alone combination either cytarabine azacitidine treatment subject Acute Myeloid Leukemia ( AML ) fail standard treatment , subject without prior therapy refuse standard chemotherapy .</brief_summary>
	<brief_title>A Multicenter Open-Label Phase 2a Study Ibrutinib Monotherapy Combination With Either Cytarabine Azacitidine Subjects With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Male female ≥ 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Subjects pathologically document AML fail standard treatment , subject without prior therapy refuse standard treatment option Bone marrow aspirate/biopsy result show &gt; 5 % blast WBC count &lt; 25,000 cells/mm3 ( 25 x 109/L ) Platelet count &gt; 10,000 cells/mm3 ( 10 x 109/L ) Adequate hepatic renal function define : For Cohorts 1 2 : serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤3.0 x upper limit normal ( ULN ) ; Cohort 3 : ALT ≤2.5 AST ≤2.5 ULN . Serum creatinine ≤2 mg/dL Estimated Creatinine Clearance ≥30 mL/min ( CockcroftGault ) . Bilirubin ≤1.5 x ULN ( unless bilirubin rise due Gilbert 's syndrome nonhepatic origin ) . PT/INR &lt; 1.5 x ULN PTT ( aPTT ) &lt; 1.5 x ULN ( When treat warfarin vitamin K antagonist , INR ≤3.0 ) . Female subject nonreproductive potential ( Female subject reproductive potential must negative serum pregnancy test upon study entry ) . Male female subject reproductive potential agree use highly effective method birth control ( e.g. , condom , implant , injectables , combine oral contraceptive , intrauterine device [ IUDs ] , complete abstinence , sterilize partner ) period therapy 90 day last dose study drug . Acute promyelocytic leukemia ( FrenchAmericanBritish Class M3 AML ) . Known active central nervous system ( CNS ) leukemia . Known active systemic infection ( Grade ≥2 ) . Active bleeding disorder clinical sign bleed ( Grade ≥2 ) . Prior bone marrow transplant require immunosuppressant therapy present graft vs host disease ( GVHD ) . History malignancy , except : Malignancy treat curative intent know active disease present ≥3 year first dose study drug low risk recurrence treat physician . Adequately treated nonmelanoma skin cancer lentigo maligna without evidence disease . Adequately treated carcinoma situ without evidence disease . Prior treatment BTK inhibitor . For Cohort 3 subject , prior treatment hypomethylating agent ( eg , azacitidine , decitabine ) Anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal investigational therapy within 14 day 5 halflives ( whichever short ) prior first dose study drug . Subject receive monoclonal antibody anticancer intent within 8 week prior first dose study drug . Vaccinated live , attenuated vaccine within 4 week first dose study drug . Recent infection require intravenous ( IV ) systemic treatment complete ≤14 day first dose study drug . Unresolved toxicity prior anticancer therapy , define resolved Common Terminology Criteria Adverse Event ( CTCAE , version 4.03 ) , Grade 0 1 , unless otherwise define inclusion/exclusion criterion exception alopecia . Known bleed disorder ( e.g. , von Willebrand 's disease ) hemophilia . History stroke intracranial hemorrhage within 6 month prior enrollment . Known history human immunodeficiency virus ( HIV ) active hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) . Subjects positive hepatitis B core antibody hepatitis B surface antigen must negative polymerase chain reaction ( PCR ) result enrollment . Those PCR positive exclude . Major surgery within 4 week first dose study drug . Any lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion , could compromise subject 's safety put study outcome undue risk . Currently active , clinically significant cardiovascular disease , uncontrolled arrhythmia Class 3 4 congestive heart failure define New York Heart Association Functional Classification ; history myocardial infarction , unstable angina , acute coronary syndrome within 6 month prior randomization . Unable swallow capsule malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , symptomatic inflammatory bowel disease ulcerative colitis , partial complete bowel obstruction . Concomitant use warfarin Vitamin K antagonist . Requires treatment prophylaxis strong cytochrome P450 ( CYP ) 3A inhibitor Currently active , clinically significant hepatic impairment ( ≥ moderate hepatic impairment accord Child Pugh classification ) . Lactating pregnant . Unwilling unable participate require study evaluation procedure . Unable understand purpose risk study provide sign date informed consent form ( ICF ) authorization use protect health information ( accordance national local subject privacy regulation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>LD-AraC</keyword>
	<keyword>Azacitidine</keyword>
</DOC>